Our Products:
Tablets
We support diverse tablet formulations across multiple therapeutic segments using precision-controlled processes to ensure uniformity, stability and effectiveness.
Capsules
Our capsule manufacturing capabilities include both hard gelatin and advanced formulations designed for accurate dosing and improved bioavailability.
Syrups
Our liquid manufacturing facilities are equipped to deliver stable formulations with a focus on taste, consistency and microbial safety.
Ointments
We follow controlled production environments to ensure stable, and effective topical formulations for ointment.
All our products are available in low MOQ
A trusted partner that helps you stay one step ahead of the competition always
With a strong focus on highest quality standards, we manufacture pharmaceutical products that are safe, effective, and compliant with both national and international regulatory requirements.
Our state of the art manufacturing facility in Uttrakhand is WHO-GMP certefied, reflecting our strict adherence to Good Manufacturing Practices and our dedication to maintaining consistent qualtiy across all products. From sourcing premium raw materials pto implementing rigorous quality control processes, designed to exceed industry standards.
We understand the importance of reliability in the pharmaceutical supply chain. Our streamlined operations and robust logistics ensure timely deliveries, helping our partners meet market demands without compromise. In addition, we emphasize superior packaging, ensuring product integrity, stability, and an enhanced shelf presence.
Awards & Recognitions
Agnize Life Science is recognised as a winner of India CDMO awards
Latest News
Zoliflodacin: A New Oral Antibiotic Against Drug-Resistant Gonorrhea
A major recent breakthrough in antibiotic drug discovery is Zoliflodacin, a novel oral antibiotic approved in late 2025 for the treatment of uncomplicated urogenital gonorrhea in adults and adoloscents.
Vimseltinib (Romvimza) Approved for Tenosynovial Giant Cell Tumor
In early 2025, the FDA approved Vimseltinib (brand name Romvizma), a targeted CSFIR kinase inhibitor for adults with tenosynovial giant cell tumor (TGCT) who are not eligible for surgery. Unlike traditional therapies, Vimseltinib interrupts key signaling pathways in tumor-associated macrophages.
Novel Approvals Highlight Diverse Advances in 2025 Medicine
The FDA's novel drug approvals list for 2025 includes a range of innovative therapies spanning infectious diseases, cardiology, and metabolic disorders such as Nuzolvence (Zoliflodacin) for gonorrhea, alongside others like Myqorzo for obstructive cardimyopathy and Exdensur for severe asthma.
WHO-GMP Certefied Manufacturing for Reliable Pharma Products
As a trusted third-party pharma manufacturing partner in India, we support pharmaceutical brands by producing high-quality formulations at commercial scale. Our integrated approach covering production, quality control, and superior packaging ensures that products are safe, reliable, and ready for market.
